An open-source MRI scanner demonstrates innovative capabilities for in vivo testing of contrast agents in preclinical models.
N nuclei. Comprehensive documentation and complete CAD designs are provided to facilitate replication and adaptation by the research community. To illustrate the performance of the system, the results of the acquisition of NMR spectra from each nucleus are presented, as well as the first images obtained with the scanner. This platform aims to bridge the gap in preclinical low-field MRI, enabling rigorous in vivo testing of novel contrast agents and supporting broader innovation in the field.
No takes yet. Share an insight, caveat, or question.
Rodriguez et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: